Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Mateos

Showing results (171-180 of 175) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 175 results.
British Journal of Haematology|March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsLaura Rosiñol, Meral Beksac, Elena Zamagni, et al.
Blood Neoplasia|April 24, 2026
Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myelomaLorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, et al.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Leukemia|June 17, 2017
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyS K Kumar, M A Dimopoulos, E Kastritis, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
Pageof 18

Showing results (171-180 of 175) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 175 results.
British Journal of Haematology|March 16, 2021
Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerationsLaura Rosiñol, Meral Beksac, Elena Zamagni, et al.
Blood Neoplasia|April 24, 2026
Single-cell multiomics reveals regulatory mechanisms of CAR T-cell persistence and dysfunction in multiple myelomaLorea Jordana-Urriza, Guillermo Serrano, Sergio Camara-Peña, et al.
American Journal of Hematology|February 20, 2020
A multicenter retrospective study of 223 patients with t(14;16) in multiple myelomaSarah Goldman-Mazur, Artur Jurczyszyn, Jorge J Castillo, et al.
Leukemia|June 17, 2017
Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG studyS K Kumar, M A Dimopoulos, E Kastritis, et al.
Lancet (London, England)|November 15, 2020
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trialSebastian Grosicki, Maryana Simonova, Ivan Spicka, et al.
Pageof 18